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Background. Defining the parameters that modulate vaccine responses in African populations will be imper-
ative to design effective vaccines for protection against HIV, malaria, tuberculosis, and dengue virus infec-
tions. This study aimed to evaluate the contribution of the patient-specific immune microenvironment to the 
response to the licensed yellow fever vaccine 17D (YF-17D) in an African cohort.
Methods. We compared responses to YF-17D in 50 volunteers in Entebbe, Uganda, and 50 volunteers in Lau-
sanne, Switzerland. We measured the CD8+ T cell and B cell responses induced by YF-17D and correlated them 
with immune parameters analyzed by flow cytometry prior to vaccination.
Results. We showed that YF-17D–induced CD8+ T cell and B cell responses were substantially lower in immu-
nized individuals from Entebbe compared with immunized individuals from Lausanne. The impaired vac-
cine response in the Entebbe cohort associated with reduced YF-17D replication. Prior to vaccination, we 
observed higher frequencies of exhausted and activated NK cells, differentiated T and B cell subsets and 
proinflammatory monocytes, suggesting an activated immune microenvironment in the Entebbe volun-
teers. Interestingly, activation of CD8+ T cells and B cells as well as proinflammatory monocytes at baseline 
negatively correlated with YF-17D–neutralizing antibody titers after vaccination. Additionally, memory 
T and B cell responses in preimmunized volunteers exhibited reduced persistence in the Entebbe cohort but 
were boosted by a second vaccination.
Conclusion. Together, these results demonstrate that an activated immune microenvironment prior to vaccina-
tion impedes efficacy of the YF-17D vaccine in an African cohort and suggest that vaccine regimens may need 
to be boosted in African populations to achieve efficient immunity.
Trial registration. Registration is not required for observational studies.
Funding. This study was funded by Canada’s Global Health Research Initiative, Defense Threat Reduction 
Agency, National Institute of Allergy and Infectious Diseases, Bill & Melinda Gates Foundation, and United 
States Agency for International Development.
Introduction
The yellow fever vaccine 17D (YF-17D) induces an efficient 
immune protection against infection. The protective effect of the 
vaccine is thought to occur within 10 days after vaccination in 95% 
of vaccinees and may persist for up to 30 to 35 years following 
vaccination (1–4). A booster vaccination is recommended by the 
US Centers for Disease Control and Prevention after 10 years (5, 
6); however, the World Health Organization recommends a single 
vaccination (7). This vaccine has been used recently to determine a 
gene expression signature after vaccination that highlights the fea-
tures of protective immune responses in North American adults (8, 
9). This immune response involves the coordinated induction of 
several effector arms of innate immunity as well as adaptive immu-
nity (10, 11). Studies have suggested that the ability of YF-17D to 
infect dendritic cells and activate multiple Toll-like receptors may 
be essential for generating this potent immune response (8, 12–
14). The YF-17D vaccine provides a model to study the immune 
response to vaccination in human populations, including both 
cellular and humoral responses, and to dissect the mechanisms of 
effective vaccine responses (10, 15–18). Defining vaccine efficacy 
in African populations is of paramount importance, as these pop-
ulations are targeted by most of the currently tested vaccines for 
HIV, tuberculosis, malaria, and dengue virus (DENV) (19). Of note, 
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several vaccine candidates use the YF-17D backbone as a vector for 
presentation of antigens from DENV, Japanese encephalitis virus, 
West Nile virus, and HIV (20–22).
Factors that could affect vaccine responses include genetic 
background, gender, age, and environmental differences. In a 
large study comparing the response to YF-17D in healthy adults 
from different origins, men of mixed European descent showed 
higher antibody levels when compared with females, individuals of 
African descent, or Hispanics (23), but this study did not observe 
age-related differences in vaccine responses. A large clinical trial 
in North America and the United Kingdom compared YF-17D 
immunogenicity between adults and elderly individuals and did 
not report differences in the generation of neutralizing antibod-
ies (NAbs) or differences in other quantitative responses between 
the two groups (24). However, another study analyzed the YF-17D 
response in elderly and younger subjects and showed that elderly 
individuals had a delayed antibody response and higher viremia, 
but the study did not analyze the persistence of NAb titers (25). 
These previous studies reported discrete and discordant effects of 
gender and age on the generation of antibodies against YF-17D, 
but no studies have investigated the quantitative and qualitative 
responses to YF-17D in African populations. Some reports have 
suggested that immune responses to vaccination are weaker in 
subjects from African populations as compared with that in other 
groups. Black et al. showed, by comparing two randomized con-
trolled studies in the United Kingdom and Malawi, that Bacillus 
Calmette-Guerin (BCG) vaccination induced a higher response 
in individuals from the United Kingdom when compared with 
that in those from Malawi (26). The authors 
suggested that differential sensitization due 
to exposure to environmental mycobacteria 
between the 2 populations was responsible for 
the difference in magnitude of BCG respon-
siveness. BCG vaccination was also shown to 
induce different cytokine profiles between 
United Kingdom and Malawi (27). It has 
furthermore been suggested that there is a 
reduced immune response to HIV vaccination 
in African populations when compared with a 
North American population (B003/HVTN091 
study) (28). In the present study, we compared 
the responses to YF-17D vaccination in 2 
cohorts from regions in which yellow fever 
virus (YFV) was not endemic, Lausanne, Swit-
zerland, and Entebbe, Uganda. By studying 
the immune responses to YF-17D in a Euro-
pean and an African population, we sought to 
further understand the impact of the immune 
microenvironment on vaccine efficacy in 2 dif-
ferent populations.
Results
Study population. In this study, volunteers were 
enrolled and vaccinated with the YF-17D vac-
cine in 2 different cohorts at 2 sites: Entebbe, 
Uganda, and Lausanne, Switzerland. In 
Entebbe, 50 participants were assigned to 2 
groups (Figure 1 and Table 1): the first vacci-
nation group consisted of 39 volunteers who 
received the YF-17D vaccine for the first time 
at the study; the boost vaccination group included 11 volunteers 
who had received the YF-17D vaccine at least 6 years prior to 
enrollment and who received a boost in the study. The volunteers 
were in good health. Volunteers were sampled at baseline on day 
0 and followed for 3 months after enrollment, with visits occur-
ring on days 3, 7, 10, 14, 28, and 84 (Figure 2A). Naive vaccinees 
reported more reactogenicity compared with those who were 
boosted (Supplemental Table 1; supplemental material available 
online with this article; doi:10.1172/JCI75429DS1). All adverse 
events reported during the course of the study resolved without 
sequelae (Supplemental Table 2). In Lausanne, 50 participants 
Figure 1
CONSORT diagram for (A) Lausanne and (B) Entebbe cohorts.
Table 1
Demographics of the 2 cohorts
  First vaccination Boost vaccination
  Lausanne Entebbe Lausanne Entebbe
No. of subjects 43 39 7 11
Age Mean 28 27 39 36
 SD 8 6 8 7
Gender Male 12 23 4 9
 Female 31 16 3 2
Number of subjects and age and gender of the enrolled volunteers from 
Lausanne and Entebbe in 2 groups. The first vaccination group received 
YF-17D vaccine for the first time in the study, and the boost vaccination 
group had received the YF-17D vaccine prior to the study.
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were vaccinated and grouped: 43 of the participants were YF-17D 
naive and 7 were volunteers who had received the YF-17D vaccine 
at least 10 years prior to enrollment (Figure 1 and Table 1). Three 
individuals experienced adverse events within the vaccine naive 
group (Supplemental Table 3). Volunteer samples were taken at 
baseline on day 0, and volunteers were followed for 1 year after 
enrollment, with visits occurring at days 3 and 7, week 8, and 1 
year (Figure 2A). At each time point in both cohorts, sera, plasma, 
and PBMCs were collected and processed following standardized 
standard operating procedures in both sites with good clinical 
laboratory practice compliance. Samples were frozen on site and 
shipped between sites for analysis at the required temperatures 
(LN2 for PBMCs and –80°C for plasma and sera samples). To limit 
batch effects, samples from Lausanne and Entebbe were analyzed 
simultaneously throughout the study. Demographics showed no 
differences in age between the 2 cohorts, but there was a higher 
proportion of women in the Lausanne cohort (P = 0.003) (Table 1). 
Gender was therefore tested as a variable in the study, and adjust-
ing for gender made no difference in the analyses.
We measured viremia 3 and 7 days after YF-17D vaccination 
in the plasma of vaccinees from both cohorts. YF-17D viral 
load was detected in a higher number of naive vaccinees in Lau-
sanne compared with that in those in Entebbe at day 7 (P = 0.01) 
(Figure 2B). Peak viral load was detected at day 7, and almost 
all individuals exhibited undetectable viral load at day 10 in 
Entebbe (data not shown). YF-17D vaccination induced signifi-
cantly higher viral loads in the Lausanne cohort compared with 
the Entebbe cohort 7 days after vaccination (means of 130 and 
18 copies per ml, respectively; P = 0.0007) (Figure 2C). These 
results demonstrate that the YF-17D replication was lower in 
individuals from Entebbe compared with that in those from 
Lausanne. Of note, we did not observe a significant association 
between reactogenicity and viral load in the Entebbe cohort 
(Supplemental Figure 1). To exclude the possibility that the 
lower viremia observed in the Entebbe cohort was due to cross-
NAbs against another flavivirus, we analyzed the neutraliza-
tion activity against DENV, as it is the most common mosqui-
to-transmitted viral human infection in the world (29). The sera 
of volunteers in Uganda did not show any neutralization activity 
against DENV-2 (Supplemental Figure 2, A and B). As secondary 
or more DENV infections tend to produce broadly neutralizing 
responses, these data suggest that none of the participants had 
multiple DENV exposures. Furthermore, NAbs against YF-17D 
were not detected at baseline in the vaccine- naive recipients, 
confirming that the lower response in Entebbe was not due to a 
preexisting immunity.
Heightened activation of the innate compartment in Entebbe vac-
cinees. As we observed differences in viral replication between 
the 2 groups of vaccinees, we analyzed the distribution of 
innate immune subsets that could affect viral replication, such 
as NK cells and monocytes, at baseline and after vaccination by 
flow cytometry (Supplemental Figure 3). We did not observe 
differences in the frequency of CD56+ NKp46+ NK cells within 
the lymphocytes between the Lausanne and Entebbe cohorts 
(data not shown). However, significantly higher frequen-
cies of CD16+ HLA-DR+ NK cells, considered exhausted NK 
cells, were detected at day 0, 3, and 7 in the Entebbe cohort 
when compared with the Lausanne cohort (Figure 3A). In the 
Entebbe cohort, NK cells proliferated in response to vaccina-
tion, as demonstrated by the increase in the frequency of Ki67+ 
NK cells at day 7 compared with day 0 (P = 0.04, Supplemen-
tal Figure 4A). This increase in proliferating NK cells was not 
observed in the Lausanne cohort. We further observed signifi-
cantly higher frequencies of recently activated CD16– NK cells 
secreting IFN-γ after restimulation ex vivo at all 3 time points in 
the Entebbe cohort when compared with the Lausanne cohort 
(Figure 3B). These data were supported by the observation that 
IFN-γ spontaneously secreted by PBMCs taken day 0, 3, and 7 
after vaccination was significantly higher in the Entebbe cohort 
when compared with that in the Lausanne cohort (Supplemen-
tal Figure 4B). Significantly higher frequencies of proinflam-
matory monocytes expressing CD14 and CD16 (30) were also 
observed at baseline in the Entebbe cohort when compared 
with those in the Lausanne cohort (means: 11 in the Lausanne 
cohort and 17 in the Entebbe cohort; P = 0.002) (Figure 3C). Of 
note, these monocytes expressing CD16 also expressed higher 
levels of PD-L1 and HLA-DR, corroborating their higher acti-
vation state (Supplemental Figure 4C). Overall, these results 
show a persistent proinflammatory innate compartment in the 
Entebbe cohort. The heightened activation of multiple innate 
immune subsets may play a role in the decreased viral repli-
cation of YF-17D observed in the Entebbe cohort (Figure 2C).
Figure 2
Differences in viremia after YF-17D vaccination in Lausanne and Entebbe. (A) Vaccination schedule in the 2 cohorts and longitudinal sample 
collection time points used in this study. (B) Number of naive and boosted volunteers with or without detectable viremia in the plasma by quanti-
tative RT-PCR 3 and 7 days after YF-17D vaccination. Numbers of subjects in each group are indicated within the bar graphs. VL, viral load. (C) 
YF-17D viral load measured in the plasma of naive vaccinees by quantitative RT-PCR 3 and 7 days after vaccination in Lausanne (white squares) 
and Entebbe (black dots).
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Increased baseline activation of the adaptive compartment in Entebbe 
vaccinees. We further investigated the adaptive immune response 
prior to YF-17D vaccination in the 2 cohorts by comparing the 
cellular distribution of the different T and B cell compartments at 
baseline (Supplemental Figures 5 and 6). In the CD4 T cell com-
partment, significantly higher frequencies of effector memory 
CD4 T cells were detected in the Entebbe cohort when compared 
with the Lausanne cohort (means: 6.1 in the Lausanne cohort and 
10.5 in the Entebbe cohort; P < 0.0001) (Figure 4A). The CD8 T 
cell compartment also showed a distribution toward more dif-
ferentiated cells, with significantly lower transitional memory 
CD8 T cells (means: 26.3 in the Lausanne cohort and 18.9 in the 
Entebbe cohort; P < 0.0001) but significantly higher frequencies 
of effector memory (means: 3.4 in the Lausanne cohort and 5.1 
in the Entebbe cohort; P = 0.003) and terminally differentiated 
CD8 T cells (means: 5.9 in the Lausanne cohort and 14.8 in the 
Entebbe cohort; P < 0.0001) in the Entebbe cohort (Figure 4B). 
No differences were observed in the frequencies of naive CD4 and 
CD8 T cells between the 2 cohorts (data not shown). We observed 
higher levels of activation of memory CD4 T cells, as measured by 
increased PD-1 (means: 22.1 in the Lausanne cohort and 26.9 in 
the Entebbe cohort; P = 0.0002) and ICOS expression (means: 2.4 
in the Lausanne cohort and 3.2 in the Entebbe cohort; P = 0.003) 
(Figure 4, C and D). Significantly higher frequencies of activated 
CD8 T cells expressing CD38 and HLA-DR were also observed in 
Entebbe vaccinees (means: 0.66 in the Lausanne cohort and 1.48 in 
the Entebbe cohort; P < 0.0001) (Figure 4E). Of note, no difference 
was observed in the frequency of CD4 Tregs between the 2 cohorts 
at baseline (Figure 4F). This bias toward more differentiated cells 
and higher levels of activation in both CD4 and CD8 T cells sug-
gests a more activated cellular adaptive compartment at baseline 
in Entebbe vaccinees when compared with Lausanne vaccinees.
In the B cell compartment, we observed a trend toward higher 
frequencies of tissue-like memory B cells (defined by CD19+ CD27–
 CD21–) as well as activated memory B cells (defined by CD19+ 
CD27+ CD21–) in the Entebbe cohort (Figure 5A). CD27– CD21– 
tissue-like memory B cells show characteristics of exhausted cells, 
with increased expression of inhibitory receptors and reduced 
capacity to proliferate (31, 32). Additionally, we observed a decrease 
in the frequency of naive B cells but no significant differences in 
the frequency of resting memory B cell subsets between Lausanne 
and Entebbe cohorts (Figure 5B). Interestingly, we found signifi-
cantly lower frequencies of IgM+ memory B cells (means: 41.4 in 
the Lausanne cohort and 28.9 in the Entebbe cohort; P = 0.007) 
and higher frequencies of IgG+ memory B cells (means: 28.5 in the 
Lausanne cohort and 39 in the Entebbe cohort; P = 0.004) in the 
Entebbe cohort when compared with the Lausanne cohort (Figure 
5C). Recent evidence suggests distinct functions between IgM+ and 
IgG+ memory B cells: IgM+ memory B cells are believed to retain 
broader antibody specificities, have better survival ability, and, 
more importantly, can reinitiate germinal center formation during 
secondary responses (33, 34). Thus, the high levels of IgM+ mem-
ory B cells in the Lausanne cohort could provide more flexibility 
to the overall humoral immunity. We furthermore analyzed the 
frequency of plasmablasts, defined by CD38 and CD27 expression 
prior to YF-17D vaccination, and found a significantly higher fre-
quency of plasmablasts in the Entebbe cohort compared with that 
in the Lausanne cohort (P = 0.07) (Figure 5D). The presence of 
higher levels of tissue-like memory B cells, activated B cells, IgG+ 
B cells, and plasmablasts suggests a more activated humoral com-
partment at baseline in Entebbe vaccinees when compared with 
Lausanne vaccinees.
Impaired cellular and humoral immune responses to YF-17D in Entebbe 
vaccinees. In order to analyze the impact of an activated immune 
microenvironment at baseline on the responses induced by the 
YF-17D vaccine, we measured the cellular and humoral responses 
following YF-17D vaccination. To study the CD8 T cell response 
induced by the vaccine, we selected the HLA-A*0201 subjects in 
Figure 3
Differences in innate cells between Lausanne and Entebbe cohorts. 
(A) Frequency of exhausted CD16+ HLA-DR+ NK cells in CD3– NKp46+ 
CD56+ NK cells at day 0, 3, and 7 after vaccination in Lausanne and 
Entebbe cohorts. (B) Frequency of activated CD16– NK cells in CD3– 
NKp46+ CD56+ NK cells secreting IFN-γ+ after ex vivo restimulation 
stained by intracellular cytokine staining at day 0, 3, and 7 after vac-
cination in Lausanne and Entebbe cohorts. (C) Frequency of CD14+ 
CD16+ inflammatory monocytes at baseline in Lausanne and Entebbe 
cohorts. White squares represent data points from the Lausanne 
cohort, and black dots represent data points from the Entebbe cohort.
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both cohorts to circumvent bias due to allele differences (12 in the 
Lausanne cohort and 7 in the Entebbe cohort) and used the HLA-
A*0201/LV9 tetramer directed against the dominant response to 
YFV NS4B protein (A2/NS4B) (17, 18, 35). A2/NS4B-specific CD8 
T cell responses were measured 1 year after vaccination in the Lau-
sanne cohort and 84 days after vaccination in the Entebbe cohort. 
Frequencies of A2/NS4B-specific CD8 T cells induced by the vac-
cine were significantly lower in the Entebbe cohort compared 
with those in the Lausanne cohort (means: 1.2 in the Lausanne 
cohort and 0.36 in the Entebbe cohort; P = 0.005) (Figure 6A). To 
assess the humoral immune response to YF-17D, we measured the 
YF-17D NAb titers 1 year after vaccination in the 33 donors for 
which samples were available in Lausanne and 84 days after vacci-
nation in the 50 donors in Entebbe. We observed a strong associa-
tion between the YF-17D–specific cellular and humoral responses 
after vaccination, as demonstrated by a significant correlation 
between A2/NS4B-specific CD8 T cell frequencies and YF-17D 
NAb titers (P = 0.0003) (Figure 6B). The NAb levels induced by the 
vaccine were significantly lower in the Entebbe cohort compared 
with those in the Lausanne cohort (means: –3.5 in the Lausanne 
cohort and –3.2 in the Entebbe cohort; P = 0.005) (Figure 6C). 
No significant difference in YF-17D NAb titers was observed in 
both cohorts in subjects with detectable viremia and those with 
no detectable viremia at any time point measured, suggesting that 
the level of virus replication was not the main determinant for the 
magnitude of the humoral response to YF-17D (Figure 6, D and 
E). Of note, in the Lausanne cohort, no significant difference was 
observed in NAb levels between individuals receiving the YF-17D 
vaccine alone or in combination with other immunizations (Sup-
plemental Figure 7). Adjusting for gender did not show signifi-
cant differences in NAb titers in the 2 cohorts (P = 0.23) or in each 
cohort separately (Supplemental Table 4), suggesting that this 
parameter was not a confounding factor in our study. Of note, no 
association was observed between levels of YF-17D NAb and neu-
tropenia in subjects from Entebbe (Supplemental Table 4).
Association between baseline immune activation and lower response 
to YF-17D. As we observed a higher immune activation in the 
Entebbe cohort at baseline and lower YF-17D response after 
vaccination, we looked for baseline parameters that could dic-
tate the magnitude of vaccine response among all the immune 
parameters measured at baseline. We found a strong and sig-
nificant negative correlation between the frequency of CD38+ 
CD21+ CD27– B cells, corresponding to either immature tran-
sitional B cells or activated naive B cells, and the NAb titers of 
both cohorts after YF-17D vaccination (P = 0.0004) (Figure 7A 
and Supplemental Figure 8A). A significant association was 
also found between the frequency of tissue-like memory B cells 
and lower NAb titers after YF-17D vaccination in both cohorts 
(P = 0.04) (Figure 7B and Supplemental Figure 8B). The cellular 
adaptive compartment showed a significant negative correla-
Figure 4
Baseline differences in T cell subsets between Lausanne and Entebbe cohorts. (A) Frequency of CD4 T cell memory subset distribution at base-
line in Lausanne and Entebbe cohorts for central memory (TCM), transitional memory (TTM), and effector memory CD4 T cells (TEM), defined by 
expression of CCR7, CD27, and CD45RA. (B) Frequency of memory CD8 T cell subset distribution at baseline in Lausanne and Entebbe cohorts 
for transitional memory, effector memory, and terminally differentiated CD8 T cells (TEMRA), defined by expression of CCR7, CD27, and CD45RA. 
(C) Frequency of activated cells expressing PD-1 within the memory CD4 T cells at baseline in Lausanne and Entebbe cohorts. (D) Frequency of 
activated cells expressing ICOS within the memory CD4 T cells at baseline in Lausanne and Entebbe cohorts. (E) Frequency of activated cells 
expressing CD38 and HLA-DR within the memory CD8 T cells at baseline in Lausanne and Entebbe cohorts. (F) Frequency of Treg CD4 T cells, 
defined as CD3+CD4+CD45RA–CD25+IL-7R–Foxp3+, at baseline in Lausanne and Entebbe cohorts. White squares represent data points from 
the Lausanne cohort, and black dots represent data points from the Entebbe cohort.
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tion between the expression levels of PD-1 on the memory CD8 
T cell subset and the NAb titers in both cohorts after YF-17D 
vaccination (P = 0.001) (Figure 7C and Supplemental Figure 
8C). Within the innate cell subsets at baseline, the frequency 
of CD14+ CD16+ proinflammatory monocytes was associated 
with lower NAb titers after YF-17D vaccination in both cohorts 
(P = 0.003) (Figure 7D). This association was confirmed by the 
negative correlation between the NAb titers of the Entebbe 
cohort and the amount of IL-10 secreted by baseline PBMCs 
incubated with YF-17D overnight (P = 0.04) (Figure 7E). As 
hematological data were available for the Entebbe cohort, we also 
found a strong negative correlation between the blood monocyte 
counts at baseline and the NAb titers after vaccination in the 
Entebbe cohort (P = 0.0001) (Figure 7F). No other hematological 
data at baseline were associated with NAb titers in the Entebbe 
cohort (Supplemental Table 5). As full blood data were not avail-
able for the Lausanne cohort, we could not perform the same cor-
relation analysis between the absolute count of monocytes and 
the NAb titers. Altogether, these results show that activation of 
cellular, humoral, and innate compartments prior to immuni-
zation is associated with lower NAbs after YF-17D vaccination. 
These data suggest that activation of the immune microenviron-
ment impedes the adaptive response to YF-17D vaccination.
Decreased persistence of cellular and humoral immune responses to 
YF-17D in Entebbe vaccines. As we showed a decreased magnitude of 
cellular and humoral immune responses to YF-17D in Entebbe vac-
cines, we investigated whether the persistence of YF-17D memory 
response was also impaired in this cohort. To determine the per-
sistence of YF-17D–specific CD8 T cell responses after vaccination, 
we analyzed clonal Vβ repertoire changes of the A2/NS4B-specific 
CD8 T cells at 2 different time points in the 2 cohorts (Supple-
mental Table 6). The A2/NS4B-specific CD8 T cell responses were 
composed of 3 to 7 different Vβs that were either present at the 2 
time points studied or present at a single time point. The number 
of different A2/NS4B-specific Vβs was similar for both cohorts, 
with an average of 4.5 Vβs in the Lausanne cohort and 4.6 in the 
Entebbe cohort. The A2/NS4B-specific Vβ repertoire in the Lau-
sanne cohort was composed mainly by persisting Vβs present at 
the 2 time points, with an average of 2.8 persisting and 1.6 non-
persisting Vβs. However, in the Entebbe cohort, the repertoire was 
dominated by nonpersisting Vβs, with an average of 1.5 persisting 
and 3.1 nonpersisting Vβs. Overall, the frequency of persisting A2/
NS4B-specific Vβs present at the 2 time points was significantly 
lower in YF-17D–naive vaccinated subjects from Entebbe when 
compared with that in the Lausanne cohort (means: 64 in the Lau-
sanne cohort and 32 in the Entebbe cohort; P < 0.0001) (Figure 
8A). Interestingly, in the Entebbe cohort, the frequencies of per-
sisting A2/NS4B-specific Vβs at each time point were significantly 
higher in previously vaccinated volunteers who received a second 
(boost) vaccine in this study when compared with those in naive 
vaccinees (mean: 73 in the Entebbe cohort boosted; P = 0.002) 
(Figure 8A). Of note, YF-17D–specific CD8 T cell responses were 
boosted by revaccination in the 2 HLA-A*0201–boosted subjects 
in the Entebbe cohort (Supplemental Figure 9A). We could not 
assess the second vaccine response in the Lausanne cohort, as the 
boosted subjects were not HLA-A*0201 in this cohort.
The preimmunized group in the 2 cohorts provided an oppor-
tunity to analyze the persistence of NAbs generated from the first 
YF-17D vaccination. In the Lausanne cohort, high levels of NAbs 
against YF-17D were detected already at baseline (day 3 and 7) in 
subjects that had received the YF-17D vaccine 10 years prior to 
boosting (Figure 8B), and levels remained high after boosting. Of 
note, 1 subject was not measured for NAb titers at day 7, and 2 
subjects were lost in the follow-up at 1 year. In contrast, YF-17D 
NAb levels in preimmunized subjects from Entebbe were signifi-
cantly lower at baseline (day 0 and 7) compared with those at day 
Figure 5
Baseline differences in B cell subsets between 
Lausanne and Entebbe cohorts. (A) Frequency of 
tissue-like memory B cell (CD19+CD27–CD21–) 
and activated memory B cell (CD19+CD27+CD21–) 
subsets at baseline in Lausanne and Entebbe 
cohor ts. (B) Frequency of naive (CD19+ 
CD27–CD21+) and resting memory B cell (CD19+ 
CD27+CD21+) subsets at baseline in Lausanne 
and Entebbe cohorts. (C) Frequency of IgM+ and 
IgG+ memory B cell subsets at baseline in Lau-
sanne and Entebbe cohorts. (D) Frequency of 
plasmablasts (CD38+ CD27+) in total B cells at 
baseline in Lausanne and Entebbe cohorts. White 
squares represent data points from the Lausanne 
cohort, and black dots represent data points from 
the Entebbe cohort.
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84 after boosting (P = 0.0006) and with the Lausanne cohort at 
baseline (day 3) (P = 0.0005) (Figure 8B). We observed a signifi-
cant inverse correlation between the NAb levels prior to vaccina-
tion and the increase in YF-17D NAb titers after boosting (P = 
0.0005), suggesting a negative association between preexisting 
NAbs and the boosting of B cell responses (Figure 8C). The date 
of the first YF-17D vaccination was collected for 10 of the 11 
boosted vaccinees from Entebbe. Vaccinees who received the first 
vaccination less than 7 years prior to the boosting dose showed 
detectable NAb titers against YF-17D at baseline (Figure 8D). In 
the Entebbe cohort, YF-17D–neutralizing activity was boosted by 
revaccination in both subjects with undetectable and detectable 
NAb titers at baseline (Supplemental Figure 9, B and C). Impor-
tantly, 3 of 11 preimmunized subjects in the Entebbe cohort 
showed detectable viral replication after boosting, whereas 
YF-17D viral load was not detected in any boosted vaccinees from 
Lausanne, showing that the protective effect of NAbs persisted 
for 10 years in the Lausanne cohort (Figure 8E). Of note, the 3 
boosted volunteers showing viral replication had no detectable 
NAbs at baseline, confirming the loss of NAbs after 7 years in 
the Entebbe cohort. Altogether, these results show a lower persis-
tent cellular and humoral memory response in Entebbe vaccinees 
when compared with Lausanne vaccinees after YF-17D vaccina-
tion. These data suggest that YF-17D immune responses may 
need to be boosted in Entebbe.
Discussion
We demonstrated in this study that the immune microenviron-
ment affects the quantitative and qualitative response to YF-17D. 
The Entebbe cohort showed a reduced magnitude of cellular and 
humoral responses to the vaccine, as NAb titers and YF-17D–spe-
cific CD8 T cells induced 3 months after vaccination were sig-
nificantly lower than those induced in Lausanne vaccinees after 
1 year. YF-17D induced high levels of NAbs in most individuals 
in Lausanne, whereas its efficacy was more variable in individuals 
in Entebbe, with a broader range of NAb titers (2 logs in Entebbe 
and 1 log in Lausanne). We also observed a significantly lower 
viremia in vaccinees from Entebbe when compared with the Lau-
sanne cohort but did not find an association between the level of 
viremia and the NAb titers. These data suggest that viral antigen 
load is not the main determinant for the magnitude of vaccine 
response. As we showed that the sera of Entebbe volunteers at 
baseline did not have any neutralizing activity against YF-17D or 
DENV-2, we could exclude a preexisting immunity of cross-reac-
tive antibodies as the cause of lower vaccine response in Entebbe. 
We found in this study that neither gender nor viremia affected 
the YF-17D response. We cannot rule out the impact of polymor-
phisms in genes involved in cytokines or HLA molecules in the vac-
cine response (36–39). Studies with greater numbers of volunteers 
would be required to address their effect on the YF-17D response. 
Nonetheless, our observations converged to a baseline activated 
Figure 6
Differences in A2/NS4B-specific CD8 T cells 
and NAb titers after YF-17D vaccination 
between Lausanne and Entebbe cohorts. (A) 
Frequency of A2/NS4B-specific CD8 T cells in 
HLA-A*0201 vaccinees from Lausanne (white 
squares) and Entebbe (black dots) after vac-
cination. (B) Correlation between YF-17D NAb 
titers and frequency of A2/NS4B-specific CD8 
T cells in both cohorts after vaccination. Gray 
dots depict samples from the Entebbe cohort. 
(C) YF-17D NAb titers in vaccinees from Lau-
sanne (white squares) and Entebbe (black 
dots) after vaccination. Boosted individuals in 
both cohorts are depicted in gray. (D and E) 
YF-17D NAb titers in subjects with (white tri-
angles) or without (black triangles) detectable 
viremia after vaccination (D) in the Lausanne 
cohort and (E) in the Entebbe cohort.
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immune microenvironment that could limit vaccine replication as 
well as the magnitude of YF-17D response in the Entebbe cohort. 
Indeed, we found striking differences in both innate and adaptive 
compartments between the 2 cohorts. The innate compartment 
of Entebbe volunteers prior to vaccination displayed significantly 
higher frequencies of proinflammatory monocytes, exhausted 
NK cells, and activated NK cells secreting effector molecules. The 
higher activation of NK cells has been proposed to have a nega-
tive impact on the development of T cell immunity (40, 41). In 
our study, we did not observe correlations between activated or 
exhausted NK cell subsets at baseline and YF-17D–specific B cell 
response. However, we observed an association between the fre-
quency of activated NK cells in the Entebbe cohort 7 days after 
vaccination and the NAb levels (data not shown), suggesting that 
NK cells might influence the adaptive response to YF-17D after 
vaccination. The CD14+ CD16+ monocytes have been shown to be 
increased dramatically in patients with severe infection (42, 43) 
and are a marker of ongoing activation of the immune system. The 
adaptive compartment of Entebbe vaccinees displayed more dif-
ferentiated T and B cells as well as higher frequencies of activated 
T and B cells. Interestingly, we observed increased levels of tissue-
like memory B cells in the Entebbe cohort. This B cell subset has 
been shown to be higher in diseases associated with proinflamma-
tory and chronic immune activation, such as HIV infection (31). 
We also observed an increased frequency of plasmablasts in the 
Entebbe cohort compared with that in the Lausanne cohort, sug-
gesting an increased proinflammatory environment or a height-
ened antigen triggering.
Previous reports have demonstrated the role of early innate 
responses after immunization on the vaccine response outcome 
for YF-17D (8, 9) and also for the Merck Ad5/HIV vaccine (44). 
However, we demonstrate in this study the role of baseline immune 
activation prior to immunization in the subsequent vaccine 
response. The results presented here show a profound activation 
of innate and adaptive immune cells prior to vaccination that neg-
atively affects the NAb response to YF-17D in the Entebbe cohort. 
Indeed, we showed that CD38+ CD21+ CD27– B cells, tissue-like 
memory B cells, and PD-1 expression on memory CD8 T cells 
correlate negatively with NAb titers. CD38+ CD21+ CD27– B cells 
lacking CD10 as well as PD-1 expression on CD8 T cells have been 
shown to be increased in HIV infection, in which high immune 
activation is maintained (45). Furthermore, the proinflammatory 
monocytes CD14+ CD16+ and IL-10 levels also strongly negatively 
correlated with NAb titers. Of note, the potential negative role of 
monocytes on vaccine response has been suggested in response to 
hepatitis B virus vaccination (46). We found here that the baseline 
Figure 7
Negative associations between baseline 
immune activation and YF-17D vaccine 
response. (A) Negative correlation between 
the frequency of CD38+ CD21+ CD27– B cells 
at baseline and the YF-17D NAb titers in both 
cohorts. (B) Negative correlation between 
the frequency of tissue-like memory B cells 
at baseline and the YF-17D NAb titers in both 
cohorts. (C) Negative correlation between the 
expression level of PD-1 on memory CD8 T 
cells at baseline and the YF-17D NAb titers in 
both cohorts. (D) Negative correlation between 
the frequency of CD14+ CD16+ monocytes at 
baseline and the YF-17D NAb titers in both 
cohorts. Black dots represent data points from 
the Entebbe cohort, and white dots represent 
data points from the Lausanne cohort. (E) Neg-
ative correlation between the IL-10 secretion in 
the supernatant of PBMCs at baseline stim-
ulated for 24 hours with YF-17D and the NAb 
titers in the Entebbe cohort. (F) Negative cor-
relation between the absolute monocyte count 
at baseline and the YF-17D NAb titers in the 
Entebbe cohort.
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monocyte count from the blood in the Entebbe cohort was sig-
nificantly associated with lower NAbs after YF-17D vaccination. 
This parameter could be further evaluated as a predictor of vaccine 
outcome, as it is easily quantifiable.
We demonstrated in this study that the activated immune 
microenvironment in the Entebbe cohort was associated with 
lower magnitudes of cellular and humoral responses to YF-17D 
and, even more importantly, with the reduced persistence of these 
YF-17D memory responses. In the preimmunized subjects from 
the Lausanne cohort, the NAb levels detected 10 years after vacci-
nation were similar to the levels induced 1 year after vaccination 
of the naive population, and no change in NAb titers was observed 
in these revaccinated individuals, suggesting that YF-17D induces 
high levels of persisting NAb and memory B cells in this group, 
supporting previous reports (10, 47). Strikingly, in the preimmu-
nized individuals from the Entebbe cohort, low NAb titers were 
detectable 6 years after vaccination but not after longer periods 
of time, suggesting a decay in NAb titers and a loss of memory 
B cell response over time. This may be related to the lower fre-
quency of IgM+ memory B cells observed in the Entebbe cohort. 
In the Entebbe cohort, the vaccine boost resulted in an increase 
in NAb titers with a trend toward lower NAb levels (P = 0.08) 
Figure 8
Quality of the memory T and B cell responses after YF-17D vaccination in the Lausanne and Entebbe cohorts. (A) Frequency of persisting A2/
NS4B-specific CD8 T cell clonotypes at 2 time points after first vaccination in the Lausanne cohort and after first and boosted vaccination in the 
Entebbe cohort. (B) YF-17D NAb titers in the sera of boosted vaccinees in Lausanne and Entebbe cohorts longitudinally at baseline (day 3 or 0), 
day 7, and 1 year or day 84 after vaccination. Empty squares represent data points from the Lausanne cohort, and black dots represent data 
points from the Entebbe cohort. (C) Negative association between the NAb levels detected at baseline in Lausanne and Entebbe cohorts and the 
magnitude of NAb boosting after YF-17D revaccination. Red dots depict Lausanne subjects. (D) In the boosted subjects from Entebbe, NAb titers 
against YF-17D could not be detected at baseline when the first vaccination was 7 years or more in the past. (E) Number of boosted vaccinees 
with or without detectable viremia in the plasma after YF-17D vaccination in Lausanne and Entebbe cohorts. Numbers of subjects in each group 
are indicated within the bar graphs.
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lic. Individuals willing to participate were invited for a screening visit at 
UVRI-IAVI. Volunteers received the vaccine from August to October 2009 
prior to the first documented YFV outbreak in Northern Uganda in Octo-
ber 2010 (53). In Lausanne, research participants were recruited from the 
Travellers clinic. Volunteers received the vaccine either alone or concomi-
tant with other vaccinations. This study was conducted in compliance with 
International Conference on Harmonization/good clinical practice, GCLP, 
and applicable regulatory requirements.
YF-17D production for in vitro assays. The YF-17D initial stock was obtained 
through the NIH Biodefense and Emerging Infections Research Resources 
Repository, NIAID, NIH: YFV, 17D, NR-115. YF-17D virus stocks were 
produced by infecting Vero cell monolayers grown in DMEM medium 
(Sigma-Aldrich), supplemented with 10% X-Vivo 15 medium (Lonza), 
with the YF-17D initial stock (NR-155, BEI Resources). Virus-containing 
supernatants were harvested when severe destruction of the monolayers 
was observed (6–7 days). They were cleared twice by centrifugation (750 g, 
10 minutes) and filtered through 0.45-μm PVDF syringe filters (Millipore). 
The viral particles were concentrated using Centricon Plus-20 columns 
(100-kDa cutoff; Millipore) and titrated on Vero cells by lysis plaque assay.
YF-17D viral load. YF-17D viral load was measured by ultrasensitive quan-
titative RT-PCR, as described previously (54), with slight modification. 
Viral RNA was extracted from 1 ml plasma with the Total Nucleic Acid 
Large Volume Extraction Kit (Roche Diagnostics) and was eluted in 65 μl 
elution buffer. The assay’s detection limit is 37 copies per ml of plasma.
YF-17D NAb titers. Sera from the 2 cohorts were used to measure the NAb 
titers. Briefly, serum samples were complement inactivated by means of 
30 minutes of incubation at 56°C and were then serially diluted in trip-
licates in culture medium in 96-well flat-bottomed plates. One thousand 
plaque-forming units of YF-17D were added to each well and incubated at 
37°C for 2 hours, after which 5,000 Vero cells were added. The plates were 
incubated at 37°C for 7 days, and each well was then observed under an 
inverted microscope and scored for cytopathic effect as positive (destroyed 
monolayer) or negative (intact monolayer). The highest dilution resulting 
in an intact monolayer was used as the antibody titer. YF-17D NAb titers 
are expressed in log10(highest dilution).
Analysis of A2/NS4B-specific CD8 T cells. Subjects from Lausanne and 
Entebbe cohorts were HLA typed using a 4-digit resolution in Centre 
Hospitalier Universitaire Vaudois and UVRI-IAVI, respectively. Monomers 
of HLA-A*0201 were refolded with the YFV NS4B peptide (LLWNGP-
MAV) and tetramerized freshly for each experiment with extravidin-PE 
(Sigma-Aldrich). Total CD8 T cells from HLA-A*0201–positive subjects in 
both cohorts were negatively selected by magnetic bead enrichment (Stem-
cell) and expanded for 2 weeks in the presence of PHA, feeders, and IL-2. 
Frequency of A2/NS4B-specific CD8 T cells was determined by staining for 
15 minutes at 37ºC with tetramers. Vβ usage was determined by staining 
the A2/NS4B-specific CD8 T cells with the BetaMark TCR V Kit (Beckman 
Coulter) and analyzed by flow cytometry. Vβ usage was considered positive 
with a frequency of >3%.
DENV-2 neutralizing assay. The Macaca mulatta kidney epithelial cell line 
LLC-MK2 (ATCC) was grown in DMEM 10% FBS. DENV-2 strain NG-2 was 
obtained from R. Tesh at the University of Texas at Galveston, Galveston, 
Texas, USA. Virus was propagated in LLC-MK2 cells as previously described 
(55). For the focus-forming-unit neutralization assay, LLC-MK2 target 
cells were seeded at a density of approximately 500,000 cells in each well 
of a 12-well plate 24 hours prior to DENV inoculation. Approximately 100 
focus forming units of DENV were incubated with dilutions of heat inac-
tivated patient serum in serum-free DMEM for 1 hour at 37°C. DENV/
serum mixtures were allowed to infect confluent target cell monolayers 
for 1 hour at 37°C, with rocking every 15 minutes, after which time the 
inoculum was aspirated and overlaid with fresh MEM/10% FBS containing 
after a second vaccination, suggesting that the remaining immu-
nity against YF-17D might dampen vaccine efficacy. We further 
observed a negative association between the preexisting antibodies 
against YF-17D and the magnitude of B cell boost after revaccina-
tion. Nonetheless, our observations suggest that different revac-
cination schedules should be implemented in different groups, 
depending on the persistence of their NAb titers. The correlates of 
protection of the YF-17D vaccine are difficult to establish in the 
absence of efficacy studies in humans. Only 5 cases of YFV infec-
tion have been reported in YF-17D vaccine recipients (4). How-
ever, yellow fever challenge in macaques vaccinated with YF-17D 
established that the level of protection required is log10(neutral-
ization index) > 0.7 (48). Even though we cannot link the decrease 
of NAb titers over time in the Entebbe cohort to a loss of protec-
tion against YFV, we observed a detectable viremia in 3 of the 11 
boosted volunteers, demonstrating that the previous vaccination 
did not prevent replication of the attenuated vaccine and might 
not prevent the replication of the highly replicative wild-type YFV.
The increased activation of immune microenvironment in the 
Entebbe cohort, which quantitatively and qualitatively affects 
the cellular and humoral YF-17D responses, might also reduce 
the efficacy of other vaccines. It would be important to assess 
whether this impaired adaptive immune response to YF-17D in 
the Entebbe cohort is valid for other live-attenuated vaccines 
and whether it is also applicable to killed vaccines. This baseline 
immune activation status in Entebbe could be due to several 
causes that would be difficult to tease apart in human popula-
tions. One main inducer of constant immune activation is the 
more frequent exposure to infectious diseases in Entebbe, which 
lies on the shore of Lake Victoria, when compared with the Lau-
sanne population. Chronic or acute inflammatory conditions, 
including pathogenic viral, bacterial, fungal, or parasitic infec-
tions, might play a role in this immune activation (49, 50). Of 
note, we did not observe significant differences in YF-17D NAb 
titers between individuals who reported a coinfection as an 
adverse event after vaccination and those that did not. Other 
factors, such as diet and gut microbiota, could also play a role. 
Clinical trials controlling for one or more of these parameters 
might help decipher the main causes for an activated immune 
microenvironment in the Entebbe population. Here, we analyzed 
one population in Uganda, but other studies might be needed to 
assess whether different levels of immune activation are found 
in different African populations. Specific immune modulatory 
strategies might be useful to potentiate the vaccine responses and 
memory persistence in these populations with an apparent higher 
baseline immune activation status.
Methods
Human subjects and YF-17D vaccine. This study enrolled subjects vacci-
nated with YF-17D at 2 different sites: the UVRI-IAVI in Entebbe and the 
Travellers clinic in Lausanne. The enrolled volunteers in the 2 studied 
cohorts were vaccinated with the YF-17D vaccine from Sanofi Pasteur. 
The immunogenicity of 2 different vaccine batches had been assessed in 
previous reports and showed that 2 vaccine batches provided equivalent 
protection (51, 52). The yellow fever vaccine used (Stamaril) is a live-atten-
uated preparation of the 17D strain of YFV (CDC, 1974) and is licensed in 
Uganda by the National Drug Authority. In Uganda, research participants 
were recruited from within Entebbe and Kampala through information 
presented to them in community meetings, travel clinics, hospitals, col-
leges, and other institutions and/or by advertisements to the general pub-
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A χ2 test was used to compare distributions of groups, and differences were 
considered significant at P < 0.05. To find association between the base-
line innate and adaptive parameters and the levels of YF-17D response, we 
performed a systematic correlation test between the NAb titers and every 
parameter analyzed in the study and available clinical data. Correlations 
analysis was performed using a nonparametric Spearman test, and correla-
tions were indicated with the spearman ρ value and the P value. All signifi-
cant correlations are described in the manuscript.
Study approval. The study was approved by the UVRI Science and Ethics 
Committee and the Uganda National Council for Science and Technol-
ogy, Kampala, Uganda. The ethics committee is registered with the US 
Office of Human Research Protection. The study was also approved by 
the Ethics Committee of Clinical Research from Lausanne University and 
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. Written 
informed consent was obtained from each participant prior to conducting 
any study procedures.
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1.2% microcrystalline cellulose (Avicel). Infected cells were then incubated 
at 37°C with 5% CO2 for 3 days. Infected cultures were fixed with 10% for-
malin overnight at 4°C, permeabilized with 70% ethanol for 20 minutes, 
and rinsed with PBS prior to immunostaining. Virus foci were detected 
using 1 mg/ml anti-DENV E protein human monoclonal antibody D11C 
(55) overnight at room temperature, followed by 2 mg/ml goat anti-human 
HRP (ThermoScientific) overnight at room temperature, and developed 
using 3,3′-diaminobenzidine tetrahydrochloride (Sigma-Aldrich). Results 
are expressed as the average ± SD from at least 3 replicates each.
Flow cytometry analysis. For the phenotypic analysis of NK cells, thawed 
PBMCs for each donor and each time point remained unstimulated for 
phenotyping or were stimulated with PMA/ionomycin for IFN-γ staining 
and were incubated with 1 μg/ml GolgiPlug (BD Biosciences) and 5 μg/ml 
Brefeldin (BD Biosciences) for 5 hours at 37°C. Cells were then stained 
for surface markers at 4°C for 20 minutes with the following monoclonal 
antibodies: NKp46 PE (BD Pharmingen, 9E2/Nkp46), CD56 PECy7 (BD 
Pharmingen, B159), CD16 V450 (BD Horizon, 3G8), and HLA-DR PerCP 
Cy5.5 (BD Pharmingen, G46-6 L243). Permeabilization and fixation was 
performed using the Cytofix/Cytoperm Kit (BD 554722), and intracellular 
staining was performed with IFN-γ Alexa Fluor 700 (BD Pharmingen, B27) 
monoclonal antibody for 30 minutes at room temperature, while protected 
from light. For the phenotypic analysis of CD4 and CD8 T cells, thawed 
PBMCs were stained for surface markers at 4°C for 20 minutes with the 
following monoclonal antibodies: CD8-FITC, HLA-DR-PerCP, CCR7-PE, 
PD1-PECy7, CD38-APC, CD3–Alexa Fluor 700, CD45RA-APCH7, CD4-
Qdot-655, and CD27-Qdot605 (BD Biosciences, Invitrogen). For the 
phenotypic analysis of CD4 Tregs cells and B cell subsets, thawed PBMCs 
were stained for surface markers at 4°C for 20 minutes with the follow-
ing monoclonal antibodies: CD3-A700, CD4-APC Cy7, and CD45RA-
ECD (Beckman Coulter); CD25-PE Cy5, CD38, PerCP, ICOS-PE, PD-1-
PE Cy7, CD127-Brilliant Violet 421, and FoxP3-FITC (eBioscience); and 
CD19-A700, CD27-PE, CD21-Pacific Blue, IgM-PE Cy5, and IgG-PE Cy7 
(BD Biosciences). For monocyte staining, FcR blocking was first performed 
using human TruStain FcX (BioLegend), followed by surface staining with 
the following monoclonal antibodies at 4°C for 20 minutes: CD14-PerCP 
(R&D Systems), CD16-A700 (BD Biosciences), CD3-Pacific Blue, HLA-
DR APC Cy7, CD19-PE Cy7, PD-L1-APC and PD-L2-PE. All antibodies 
were from BioLegend unless otherwise noted. Live/Dead Fixable Aqua 
(Invitrogen) was used to exclude dead cells from the analysis. Data were 
collected using an LSRII flow cytometer (BD Biosciences) and analyzed 
with FlowJo software (version 9.6.2, TreeStar Inc.) and DIVA software (ver-
sion 8.0, BD Biosciences).
Cytokine secretion analysis. Cytokine secretion of PBMCs, incubated or not 
with YF-17D at MOI 5 for 24 hours, was detected in the supernatant by 
the CBA Human Th1/Th2 Cytokine Kit, according to the manufacturer’s 
instructions. Data were collected using a FACSArray (BD Biosciences) and 
analyzed with BD FCAP array software.
Statistics. In all dot plots, horizontal bars represent the mean and the error 
bars represent the SEM. A nonparametric Mann-Whitney test was used to 
compare groups, and differences were considered significant at P < 0.05. 
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